Systemic Radiotherapy of Bone Metastases With Radionuclides.
View/ Open
Date
2021-02ICR Author
Author
Murray, I
Du, Y
Type
Journal Article
Metadata
Show full item recordAbstract
Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed.
Collections
Language
eng
Date accepted
2020-11-30
License start date
2021-02
Citation
Clinical oncology (Royal College of Radiologists (Great Britain)), 2021, 33 (2), pp. 98 - 105